Fox Chase Cancer Center Researcher Publishes New Findings on the Developmental Origin of Liver and Pancreas
PHILADELPHIA (February 27, 2001) -- Research conducted at Fox Chase Cancer Center shows that cells which develop into the liver can also give rise to part of the pancreas, according to a new study published in the March issue of Development, Volume 128(6). The finding counters the assumption that during the early stages of mammalian development, the liver and pancreas cells develop from separate lineages.
Kenneth S. Zaret, Ph.D. and his research team had originally been studying the development of the liver in mouse embryos, and then discovered that the ventral part of the pancreas develops at the same time as the liver and from the same general domain of endoderm cells. Different domains of the endoderm, an early embryonic tissue, normally differentiate into liver, lung, pancreas, thyroid, and intestine; yet how these diverse tissue domains are specified, and whether each tissue domain can give rise to other tissue derivatives, has been unclear. Differentiation is the process whereby embryonic cells become specialized in structure and function, and organize into the tissues and organs that make up the adult organism.
The goal of this research was to understand basic principles by which different cell types arise from a common cell population.
Dr. Zaret's group hypothesized that early embryonic cells that normally become the liver may also have the capacity to become the ventral part of the pancreas. They previously developed techniques for isolating cells from the ventral endoderm of a mouse embryo and for culturing the cells in the laboratory, allowing the researchers to closely follow the generation of the liver or pancreatic cell lineages.
Earlier, they used this culture method to show that fibroblast growth factor (FGF), a signal secreted from embryonic heart tissue, would cause nearby ventral endoderm cells to initiate liver development. The embryonic liver normally originates next to the cardiac domain. In the present study, Dr. Zaret's group showed that in the absence of cardiac FGF signaling, the ventral endoderm cells would initiate pancreas development instead of that for liver. They concluded that by default, the cells in this domain of the endoderm will differentiate into pancreas cells, and the role of FGF signaling from the heart is to divert some of the endoderm cells from a pancreatic fate to a liver fate.
The embryonic precursor cells that Dr. Zaret's laboratory studied therefore undergo a choice whereby they can become either the liver or the ventral pancreas, depending on the presence of a signaling factor. The researchers could control endoderm differentiation into either early liver cells or early pancreas cells at will, by manipulating the cell culture conditions.
When asked about the significance of the findings, Zaret explained. ""It offers an explanation for the puzzling emergence of liver cells in the pancreas during certain pathological states. The work provides a new direction for the pancreatic development field, since it reveals a common relation between the pancreas and liver, overturning the previously held notion that there was no developmental link between the two. Understanding how signaling and gene regulatory factors control the development of the liver and ventral pancreas should provide important insights on how to control the differentiation state of life-threatening cells which surface during carcinogenesis or chronic tissue damage, as well as during metabolic diseases."
Zaret's research is supported by a grant from the Institute of General Medical Sciences at the National Institutes of Health. His studies on cell signaling and genetic control are an example of the importance of basic research to the control of health and disease. He conducted this research in collaboration with Joonil Jung at Fox Chase and Gail Deutsch, Minghua Zheng, and Jos Lra of Brown University. The study can be found on the Development website at www.biologists.com/development.
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.